收费全文 | 197122篇 |
免费 | 16642篇 |
国内免费 | 7110篇 |
耳鼻咽喉 | 1611篇 |
儿科学 | 2573篇 |
妇产科学 | 2166篇 |
基础医学 | 30953篇 |
口腔科学 | 3293篇 |
临床医学 | 14364篇 |
内科学 | 35262篇 |
皮肤病学 | 2681篇 |
神经病学 | 14743篇 |
特种医学 | 4193篇 |
外国民族医学 | 52篇 |
外科学 | 13203篇 |
综合类 | 26085篇 |
现状与发展 | 19篇 |
一般理论 | 6篇 |
预防医学 | 9733篇 |
眼科学 | 1959篇 |
药学 | 31961篇 |
44篇 | |
中国医学 | 8153篇 |
肿瘤学 | 17820篇 |
2024年 | 511篇 |
2023年 | 3801篇 |
2022年 | 8266篇 |
2021年 | 10017篇 |
2020年 | 7535篇 |
2019年 | 6419篇 |
2018年 | 6177篇 |
2017年 | 6192篇 |
2016年 | 6320篇 |
2015年 | 7436篇 |
2014年 | 11506篇 |
2013年 | 12811篇 |
2012年 | 11364篇 |
2011年 | 13123篇 |
2010年 | 10824篇 |
2009年 | 11084篇 |
2008年 | 10751篇 |
2007年 | 9774篇 |
2006年 | 8725篇 |
2005年 | 7666篇 |
2004年 | 6390篇 |
2003年 | 5717篇 |
2002年 | 4537篇 |
2001年 | 3701篇 |
2000年 | 3125篇 |
1999年 | 2826篇 |
1998年 | 2636篇 |
1997年 | 2446篇 |
1996年 | 2188篇 |
1995年 | 1943篇 |
1994年 | 1761篇 |
1993年 | 1525篇 |
1992年 | 1280篇 |
1991年 | 1207篇 |
1990年 | 991篇 |
1989年 | 832篇 |
1988年 | 792篇 |
1987年 | 665篇 |
1986年 | 600篇 |
1985年 | 945篇 |
1984年 | 900篇 |
1983年 | 630篇 |
1982年 | 639篇 |
1981年 | 511篇 |
1980年 | 431篇 |
1979年 | 353篇 |
1978年 | 230篇 |
1977年 | 193篇 |
1976年 | 183篇 |
1975年 | 123篇 |
The common marmoset (Callithrix jacchus) is a useful experimental animal to evaluate the pharmacokinetics of drug candidates. Cytochrome P450 (P450) 2B enzyme in marmoset livers has been identified; however, only limited information on the enzymatic properties and distribution has been available.
Marmoset P450 2B6 amino acids showed high sequence identities (>86%) with those of primates including humans and cynomolgus monkeys. Phylogenetic analysis using amino acid sequences indicated that marmoset P450 2B6 was closer to human and cynomolgus monkey P450 2B6 than to P450 2B orthologs of other species, including pigs, dogs, rabbits and rodents.
Quantitative polymerase chain reaction analysis using specific primers showed P450 2B6 mRNA predominantly expressed in livers among the five marmoset tissues, similar to those of humans and cynomolgus monkeys.
Marmoset P450 2B6 heterologously expressed in Escherichia coli membranes oxidized 7-ethoxycoumarin, pentoxyresorufin, propofol and testosterone, at roughly similar rates to those of humans and/or cynomolgus monkeys. A high capacity of marmoset P450 2B6 with propofol 4-hydroxylation (at low ionic strength conditions) with a low Km value was relatively comparable to that for marmoset livers.
These results collectively indicated a high propofol 4-hydroxylation activity of P450 2B6 expressed in marmoset livers.
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献